Smith & Nephew Receives FDA Clearance for ACTICOAT Moisture Control
NEW YORK -- Smith & Nephew's U.S. Advanced Wound Management division today announced that the Food and Drug Administration (FDA) has given clearance of its newest absorbent antimicrobial barrier dressing, ACTICOAT Moisture Control.
The clearance and introduction of ACTICOAT Moisture Control complements the company's existing ACTICOAT range. These wound-care products to feature the patented Silcryst nanocrystalline silver technology that provides antimicrobial barrier protection.
ACTICOAT Moisture Control was developed over the last two years, through collaboration between Smith & Nephew and NUCRYST Pharmaceuticals. Smith & Nephew launched the product at the SAWC Convention on April 22 in San Diego, as an extension to the existing ACTICOAT family.
The current ACTICOAT range, which encompass a three-day, seven-day and absorbent product have been shown to be bactericidal against a broad range of pathogens, including MRSA and VRE, and have led the way in both burn and chronic wound care. ACTICOAT Moisture Control, with an extended wear time up to seven days, reduces the number of dressing changes and the resources needed to change multiple dressings, adding to the comfort and quality of life of the patient.
Antimicrobial barrier dressings are increasingly used in the advanced wound care market as a barrier to bacterial penetration, a major cause of delays and complications to wound healing. As an effective barrier to pathogenic bacteria, ACTICOAT Moisture Control may help avoid serious complications associated with nosocomial outbreaks, wound infection may be avoided and duration of hospitalization and healthcare related costs reduced proportionately.
The introduction of ACTICOAT Moisture Control now offers the bactericidal protection synonymous with the ACTICOAT range in a highly absorbent, easy-to-use format. New ACTICOAT Moisture Control eliminates the threats to healing and provides powerful antimicrobial barrier protection to chronic and acute wounds.
"We are very excited to announce that we have added ACTICOAT Moisture Control to the Smith & Nephew portfolio. This new product allows us to provide even more options for our valued customers as they treat wounds that affect their patients. We strive to help people regain their lives and the addition of ACTICOAT Moisture Control will help us do just that," says Jim Lodigiani, U.S. wound management president.
Source: Smith & Nephew, Inc.
Back to Basics: Hospital Restores Catheter-Associated UTI Rates to Prepandemic Baseline
June 16th 2025A 758-bed quaternary medical center slashed catheter-associated urinary tract infections (CAUTIs) by 45% over 2 years, proving that disciplined adherence to fundamental prevention steps, not expensive add-ons, can reverse the pandemic-era spike in device-related harm.
Beyond the Surface: Tackling the Sterilization Challenges of Flexible Endoscopes
May 26th 2025Flexible endoscopes revolutionized modern medicine—but their complex design poses persistent sterilization challenges. With mounting infection risks and emerging innovations, experts are rethinking how to clean and safeguard one of health care’s most indispensable tools.
Silent Saboteurs: Managing Endotoxins for Sepsis-Free Sterilization
Invisible yet deadly, endotoxins evade traditional sterilization methods, posing significant risks during routine surgeries. Understanding and addressing their threat is critical for patient safety.
